Daraxonrasib

The Guardian reports that the U.S. Food and Drug Administration granted expedited approval to daraxonrasib, an oral, first-of-a-kind pill that the article says block...

A randomized clinical trial of about 500 patients with metastatic pancreatic cancer that had progressed after prior treatment found that the experimental oral drug d...

Vicky Stinson, a 65‑year‑old diagnosed with Stage III pancreatic cancer in 2024, participated in a clinical trial of daraxonrasib, an oral RAS inhibitor. After 13 mo...

The FDA has authorized expanded access (compassionate use) to daraxonrasib, an investigational oral medication developed by Revolution Medicine, for patients with pr...